Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Effect of Elastic Chest Compression on Functional Exercise Capacity and Respiratory Performance in Patients With COPD

NCT06519474 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2024-07-10
Last updated
2024-07-25

Condition(s) studied

COPDHyperinflation

Investigational drug(s) / intervention(s)

Theraband chest compression

Theraband chest compression: Chest compression applicated via a Red Theraband over the upper or lower chest region

Study summary

The goal of this clinical trial is to investigate the effects of elastic chest compression on functional exercise capacity and respiratory performance of patients with COPD. The main questions it aims to answer are:

Is there difference in functional exercise capacity and respiratory performance without or with the use of elastic upper chest compression? Is there difference in functional exercise capacity and respiratory performance between the use of elastic upper chest compression and elastic lower chest compression?

Participants will:

Be evaluated under three conditions on three different days: without elastic compression, with upper chest compression, and with lower chest compression, with the order of compression application randomly assigned.

The functional capacity and respiratory muscle performance of all patients will be evaluated.

The days for evaluation will be at least three days apart from each other.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * at least 20 years old * has a clinical diagnosis of COPD without infection or acute exacerbation in the previous four weeks * is capable of cooperating with the required tests and measurements of the study Exclusion Criteria: * has any clinical diagnosis that could affect test outcomes (e.g., neuromyopathy) * has experienced unstable angina or an acute myocardial infarction within the last month * has adjusted COPD related medication within the last month * a Mini-Mental State Examination (MMSE) score below 24

Primary outcome measure(s)

  • Functional exercise capacity — up to 3 weeks
    6 minute walk test measured in meters
  • Respiratory muscle performance — up to 3 weeks
    Maximum inspiratory (MIP) and expiratory pressures (MEP) in mmH2O
  • Respiratory flow performance — up to 3 weeks
    peak inspiratory (PIFR) and expiratory flows (PEFR) in liter per minute

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Hsinchu Branch Hsinchu Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06519474 on ClinicalTrials.gov ↗ ← All trials in Taiwan